Brokerages expect Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to announce earnings of ($0.34) per share for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Tetraphase Pharmaceuticals’ earnings. The highest EPS estimate is ($0.26) and the lowest is ($0.40). Tetraphase Pharmaceuticals reported earnings of ($0.63) per share in the same quarter last year, which would suggest a positive year over year growth rate of 46%. The firm is expected to announce its next quarterly earnings report on Thursday, November 1st.
According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year earnings of ($1.39) per share for the current fiscal year, with EPS estimates ranging from ($1.82) to ($1.03). For the next fiscal year, analysts forecast that the company will report earnings of ($1.18) per share, with EPS estimates ranging from ($1.77) to ($0.81). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.18. Tetraphase Pharmaceuticals had a negative net margin of 421.64% and a negative return on equity of 67.34%. The business had revenue of $11.58 million during the quarter, compared to analysts’ expectations of $2.23 million.
Large investors have recently bought and sold shares of the stock. Deutsche Bank AG boosted its position in Tetraphase Pharmaceuticals by 168.6% in the 4th quarter. Deutsche Bank AG now owns 221,425 shares of the biopharmaceutical company’s stock valued at $1,394,000 after buying an additional 138,996 shares during the period. BlackRock Inc. boosted its position in Tetraphase Pharmaceuticals by 21.2% in the 4th quarter. BlackRock Inc. now owns 4,044,340 shares of the biopharmaceutical company’s stock valued at $25,479,000 after buying an additional 707,296 shares during the period. Two Sigma Investments LP boosted its position in Tetraphase Pharmaceuticals by 276.7% in the 4th quarter. Two Sigma Investments LP now owns 64,413 shares of the biopharmaceutical company’s stock valued at $406,000 after buying an additional 47,313 shares during the period. Alambic Investment Management L.P. purchased a new position in Tetraphase Pharmaceuticals in the 1st quarter valued at approximately $356,000. Finally, Renaissance Technologies LLC boosted its position in Tetraphase Pharmaceuticals by 77.6% in the 4th quarter. Renaissance Technologies LLC now owns 592,493 shares of the biopharmaceutical company’s stock valued at $3,733,000 after buying an additional 258,908 shares during the period. 43.32% of the stock is owned by hedge funds and other institutional investors.
Shares of Tetraphase Pharmaceuticals stock traded down $0.14 during mid-day trading on Friday, hitting $2.95. The stock had a trading volume of 942,788 shares, compared to its average volume of 1,051,855. Tetraphase Pharmaceuticals has a 12-month low of $2.05 and a 12-month high of $7.98. The stock has a market cap of $170.21 million, a price-to-earnings ratio of -1.12 and a beta of 2.44.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.